Cargando…

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer

PURPOSE: Dysregulation of the PI3K pathway is one of the most common events in breast cancer. Here we investigate the activity of the PI3K inhibitor MEN1611 at both molecular and phenotypic levels by dissecting and comparing its profile and efficacy in HER2 + breast cancer models with other PI3K inh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiascarelli, Alessio, Merlino, Giuseppe, Capano, Stefania, Talucci, Simone, Bisignano, Diego, Bressan, Alessandro, Bellarosa, Daniela, Carrisi, Corrado, Paoli, Alessandro, Bigioni, Mario, Tunici, Patrizia, Irrissuto, Clelia, Salerno, Massimiliano, Arribas, Joaquin, de Stanchina, Elisa, Scaltriti, Maurizio, Binaschi, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147754/ https://www.ncbi.nlm.nih.gov/pubmed/36913051 http://dx.doi.org/10.1007/s10549-023-06895-2

Ejemplares similares

Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients
por: Tosca, Elena M., et al.
Publicado: (2023)

The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway
por: Papoff, Giuliana, et al.
Publicado: (2023)

PIK3CA-mutations in breast cancer
por: Reinhardt, Kristin, et al.
Publicado: (2022)

Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics
por: Lewis Phillips, Gail, et al.
Publicado: (2021)

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
por: Dubash, Taronish D., et al.
Publicado: (2023)

Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin
por: Turturro, Sanja B., et al.
Publicado: (2016)

Activity of trastuzumab emtansine (T-DM1) in 3D cell culture
por: Boyer, Jean Zheng, et al.
Publicado: (2021)

Fugitive Sheet Dated 1611
Publicado: (1923)

Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis
por: Lewis Phillips, Gail D., et al.
Publicado: (2017)

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
por: Gaudio, Eugenio, et al.
Publicado: (2020)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients
por: Papautsky, Elizabeth Lerner, et al.
Publicado: (2022)

Anti-tumour activity of tachykinin NK(1)receptor antagonists on human glioma U373 MG xenograft
por: Palma, C, et al.
Publicado: (2000)

The first cataract surgeons in Latin America: 1611–1830
por: Leffler, Christopher T, et al.
Publicado: (2016)

1611 Antibodies to conformational epitopes interfere with T20 fusion inhibition
por: Sojar, Hakimuddin, et al.
Publicado: (2014)

OC125, M11 and OV197 Epitopes Are Not Uniformly Distributed in the Tandem-Repeat Region of CA125 and Require the Entire SEA Domain
por: Bressan, Alessandro, et al.
Publicado: (2013)

Open channel block of Kv1.5 channels by HMQ1611
por: Dong, Chao, et al.
Publicado: (2022)

Vida del soldado español Miguel Castro, 1593-1611 : escrita por el mismo.
por: Castro, Miguel de, b.1593-
Publicado: (1949)

1611. Interventions to Decrease the Absolute Number of Individuals Not Immune to Measles at Princeton University (PU)
por: Daskalaki, Irini, et al.
Publicado: (2019)

Genetic Catalytic Inactivation of GRK5 Impairs Cardiac Function in Mice Via Dysregulated P53 Levels
por: Marzano, Federica, et al.
Publicado: (2022)

Social threat exposure in juvenile mice promotes cocaine‐seeking by altering blood clotting and brain vasculature
por: Lo Iacono, Luisa, et al.
Publicado: (2016)

1611P Clinical determinants of SARS-CoV-2 vaccine response in adults with cancer
por: Segelov, E., et al.
Publicado: (2022)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Patra, Satyajit, et al.
Publicado: (2017)

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model
por: Dirican, Ebubekir
Publicado: (2020)

Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study
por: Coppini, Raffaele, et al.
Publicado: (2019)

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
por: Chandarlapaty, Sarat, et al.
Publicado: (2009)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Systems Analysis Implicates WAVE2 Complex in the Pathogenesis of Developmental Left-Sided Obstructive Heart Defects
por: Edwards, Jonathan J., et al.
Publicado: (2020)

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
por: Cizkova, M, et al.
Publicado: (2013)

Tumor Growth in the High Frequency Medulloblastoma Mouse Model Ptch1(+/−)/Tis21(KO) Has a Specific Activation Signature of the PI3K/AKT/mTOR Pathway and Is Counteracted by the PI3K Inhibitor MEN1611
por: Ceccarelli, Manuela, et al.
Publicado: (2021)

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
por: Fuentes, Gloria, et al.
Publicado: (2011)

CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia
por: Yakymiv, Yuliya, et al.
Publicado: (2019)

1611. Evaluating Clinical Outcomes and Efficacy of Daptomycin in Combination with a Beta-Lactam for the Treatment of Vancomycin-Resistant Enterococcus (VRE) Bacteremia
por: Irusta, Nerea, et al.
Publicado: (2020)

P1611: INSIGHTS INTO FACILITATED IMMUNOGLOBULIN (FSCIG) USE IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DISEASES: FINAL RESULTS FROM THE FIGARO STUDY
por: Dimou, M., et al.
Publicado: (2022)

Central carbon metabolism in the progression of mammary carcinoma
por: Richardson, Adam D., et al.
Publicado: (2007)

The spectrum of ATM missense variants and their contribution to contralateral breast cancer
por: Broeks, Annegien, et al.
Publicado: (2007)

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases
por: Rajput, Ashish B., et al.
Publicado: (2007)

Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer
por: van der Groep, Petra, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_3vji8ij6m6mcugqo0rau39pfni